Navigation Links
MultiCell and University Health Network Will Evaluate Two Potential Therapies for Liver Cancer Treatment
Date:7/11/2011

WOONSOCKET, R.I., July 11, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer.  The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells will also be evaluated.  

The role of liver stem cells in the carcinogenic process has led researchers to hypothesize that primary liver cancer arises by maturation arrest of liver stem cells.  While progress has been made in developing cancer therapies that result in cytoreduction, the control of cancer over a longer interval and especially of metastatic disease remains a key goal.  Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies.  MultiCell owns exclusive rights to several issued U.S. patents and corresponding foreign patents related to the isolation and differentiation of liver stem cells.  

Primary liver cancer resulting from Hepatitis B and Hepatitis C infection is the most common cancer in the world with more than 1 million new cases diagnosed each year.  Primary liver cancer is rarely discovered early and often does not respond to treatment.

"We are pleased to have the opportunity to work with Dr. Ghanekar and his colleagues at Toronto General Hospital," said W. Gerald Newmin, Chairman and Chief Executive Officer of MultiCell.  "Dr. Ghanekar is one of the leading researchers in the field of liver cancer, and we are hopeful MCT-465 and MCT-485 will prove effective when evaluated in models of primary liver cancer," Mr. Newmin stated.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

About University Health Network

University Health Network, consisting of Toronto General Hospital, Toronto Western Hospital and Princess Margaret Hospital, is one of Canada's largest research hospitals.  Among many discoveries, researchers at University Health Network were first to discover the existence of cancer stem cells.  Primary funding for the University Health Network comes from Canada's Ontario Ministry of Health.  For more information about the University Health Network, please visit http://www.uhn.ca.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2010, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
3. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
4. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
5. MultiCell Technologies Launches New Web Site
6. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
7. MultiCell Technologies is Granted Stem Cell Patent
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Boston University Biomedical Engineers Find Chink in Bacterias Armor
10. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... efforts to develop sutezolid as effective response to infectious ... TB Alliance and the Medicines Patent Pool (MPP) announced ... an antibiotic drug candidate which demonstrated encouraging results in ... sutezolid in combination with other TB drugs and follows ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Cryostat Market ... the next decade to reach approximately $3.5 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Viewers who ... variety of critical historical facts, cultural practices, goods, services, and societal issues tend to ... will look into the popular practice of utilizing running events for causes around the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in ... and leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance ... is designed to teach how to maximize their sales efforts, as well as ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion ... to Walk with God #TruthwithGrace” is the creation of published author Lea Michelle ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The ... silly dog who lives his life to the fullest, as God intended. “The Adventures ... Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially about truth ...
Breaking Medicine News(10 mins):